SRNE Stock Recent News
SRNE LATEST HEADLINES
Scilex is majority owned by Sorrento, a company I will not invest in. Scilex is a more regular company, doing R&D work, selling drugs and so on. However, it is still entangled with Sorrento, and its stock price movement is too erratic for me.
Any euphoria after the biotech stock's big jump yesterday didn't last long.
Sorrento Therapeutics (NASDAQ: SRNE ) stock is trending on social media today, with SRNE stock up 8% at one point this morning. This climb came after shares soared roughly 25% yesterday, although SRNE is now in the red.
Will penny stock news put these on your buy or sell list this week? The post Penny Stocks To Buy?
Use these tips for staying disciplined when it comes to investing in penny stocks The post How to Stay Disciplined When Investing in Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The company is walling off subsidiary Scilex from its bankruptcy proceedings.
Penny stocks with big news in February 2023. Are they the best to buy now?
Use these tips for identifying penny stocks trends in 2023 The post How to Identify Trends With Penny Stocks in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The heavy selling pressure might have exhausted for Sorrento Therapeutics (SRNE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Sorrento Therapeutics (NASDAQ: SRNE ) is down by more than 60% today following the company's announcement that it would file for Chapter 11 bankruptcy. Scintilla Pharmaceuticals, a wholly owned subsidiary of Sorrento, will also file for Chapter 11.